Once-daily rabeprazole, levofloxacin, clarithromycin-MR, and bismuth for Helicobacter pylori eradication: A randomized study of 7 or 14 days (ONCE study)
Helicobacter Jul 16, 2019
Auttajaroon J, et al. - In this prospective randomized pilot study, researchers assessed a once-daily dosing H. pylori eradication regimen. The compared a once-daily treatment regimen containing levofloxacin (750 mg), clarithromycin-MR (1 g), rabeprazole (60 mg), and bismuth subsalicylate (1,048 mg) for 7 or 14 days. A full 100 participants were randomized. High eradication rate was achieved with once-daily 14-day rabeprazole-, levofloxacin-, clarithromycin-MR-, and bismuth-containing therapy— suggesting the high efficacy of triple therapies with a proton-pump inhibitor, bismuth, and clarithromycin-MR or levofloxacin for once-a-day tailored therapy or as empiric therapy for first-line regimen.
Sign-up to continue reading. It is free & takes less than 2 mins
45 lakhs+ doctors trust M3 globally
Free & unlimited access to original articles and quizzes
Secure: we never sell your data
Sign up with M3 India to try daily quizzes and take part in competitionsTry M3 India / Log In
Why join our Market Research Panel?
- 10K+ Doctors participated in 40+ Indian and Global studies in 2018
- Average honorarium per study was Rs. 1,600 and total honoraria as high as Rs. 12,000 was earned by a Doctor